Published in J Invest Dermatol on May 01, 2000
Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One (2013) 1.02
Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 1.01
Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun (2007) 0.80
IFN-gamma suspends the killing license of anti-tumor CTLs. J Clin Invest (2002) 0.78
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 4.20
The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci (2000) 3.70
Botulinum toxin for palmar hyperhidrosis. Lancet (1997) 3.17
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98
Antigen presentation in extracellular matrix: interactions of T cells with dendritic cells are dynamic, short lived, and sequential. Immunity (2000) 2.93
Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res (1998) 2.44
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest (1996) 2.10
Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol (1998) 2.09
Nonsense suppressors of Saccharomyces cerevisiae can be generated by mutation of the tyrosine tRNA anticodon. Nature (1976) 2.07
Biosynthesis of the beta and beta' subunits of RNA polymerase in Escherichia coli. J Mol Biol (1973) 2.03
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer (1976) 1.97
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum (2006) 1.96
Replication of the F'lac sex factor in the cell cycle of Escherichia coli. Mol Gen Genet (1971) 1.92
Cell migration strategies in 3-D extracellular matrix: differences in morphology, cell matrix interactions, and integrin function. Microsc Res Tech (1998) 1.86
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest (2000) 1.85
Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol (2000) 1.82
Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res (2001) 1.82
Amoeboid leukocyte crawling through extracellular matrix: lessons from the Dictyostelium paradigm of cell movement. J Leukoc Biol (2001) 1.78
A monoclonal antibody to a differentiation antigen present on mature human macrophages and absent from monocytes. J Immunol (1985) 1.76
Hailey-Hailey disease. Eradication by dermabrasion. Arch Dermatol (1994) 1.73
Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res (2000) 1.67
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene (1999) 1.59
Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res (2001) 1.59
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). J Natl Cancer Inst (1980) 1.53
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer (1994) 1.53
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52
Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res (2000) 1.51
Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J Cell Biol (1996) 1.50
Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res (1999) 1.46
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Should elective lymph node dissection be used for treatment of primary melanoma? J Cancer Res Clin Oncol (1989) 1.44
Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer (1987) 1.41
Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int J Cancer (1976) 1.41
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood (1998) 1.41
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol (2004) 1.39
Higher-order structure of human mitotic chromosomes. Proc Natl Acad Sci U S A (1977) 1.38
Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res (1997) 1.38
Anorectal melanoma: surgical management guidelines according to tumour thickness. Br J Cancer (2003) 1.37
Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol Biol Cell (1999) 1.33
Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol (2000) 1.32
Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia (2006) 1.31
Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J (1986) 1.31
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 1.27
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity (2001) 1.26
Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood (2001) 1.25
Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J Invest Dermatol (1996) 1.24
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol (1999) 1.24
Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol (2000) 1.24
Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res (1995) 1.24
Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer (1980) 1.19
Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol (1999) 1.19
Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res (1997) 1.17
Simulation of the electrical and mechanical gradient of the small intestine. Am J Physiol (1968) 1.17
Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol (1993) 1.17
Induction of carcinoma cell migration on vitronectin by NF-kappa B-dependent gene expression. Mol Biol Cell (1995) 1.16
Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol (1999) 1.16
Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J Biol Chem (1985) 1.15
The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-alpha-induced expression of monocyte-chemoattractant protein-1 in endothelial cells. Blood (1999) 1.15
Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother (1998) 1.15
Listeria monocytogenes-infected human dendritic cells: uptake and host cell response. Infect Immun (2000) 1.14
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Phylogeny and dating of some pathogenic keratinophilic fungi using small subunit ribosomal RNA. J Med Vet Mycol (1996) 1.14
Activation of nuclear factor-kappa B and gene expression in human endothelial cells by the common haptens nickel and cobalt. J Immunol (1995) 1.14
The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines. J Invest Dermatol (1997) 1.13
Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer (1985) 1.12
Merkel cell carcinoma--pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol (2011) 1.12
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol (2000) 1.12
IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol (2000) 1.11
Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci (1996) 1.11
Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology (1997) 1.11
Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat (1997) 1.09
Transformation induced by Epstein-Barr virus and the role of the nuclear antigen. Cold Spring Harb Symp Quant Biol (1980) 1.08
Migration of dendritic cells within 3-D collagen lattices is dependent on tissue origin, state of maturation, and matrix structure and is maintained by proinflammatory cytokines. J Leukoc Biol (2000) 1.08
Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis (1991) 1.07
Immunohistochemistry in the evaluation of melanocytic tumors. Semin Diagn Pathol (1993) 1.07
Asymptomatic carriage of toxigenic Clostridium difficile by hospitalized patients. J Hosp Infect (2013) 1.07
HLA antigen expression at the single cell level on a K562 X B cell hybrid: an analysis with monoclonal antibodies using bacterial binding assays. Somatic Cell Genet (1982) 1.06
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res (2007) 1.06
Phenotype of normal cutaneous microvasculature. Immunoelectron microscopic observations with emphasis on the differences between blood vessels and lymphatics. J Invest Dermatol (1996) 1.05
Migration of dendritic cells in 3D-collagen lattices. Visualisation of dynamic interactions with the substratum and the distribution of surface structures via a novel confocal reflection imaging technique. Adv Exp Med Biol (1997) 1.05
Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med (1999) 1.05
Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol (2007) 1.04
Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol (2000) 1.04
Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology (1994) 1.04
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer (2002) 1.03